Market intelligence, trend analysis and forecasts for the Pharma and Healthcare industries across the regions

Industry / China

Why Bupa Chose India Over China

May 2010 | Industry Trend Analysis

BMI View: China's pharmaceutical market is more attractive to Western firms than India's. Absolute spending on medicines is higher (US$45.5bn in China versus US$17.1bn in India) and annual per-capita expenditure is greater (US$34.2 vs US$14.6) While India has a superior five-year compound annual growth rate (CAGR) (14.1% vs 12.3%) and higher spending as a percentage of GDP (1.30% vs 0.97%), the intellectual property/pricing/reimbursement regime is much better in China. Accordingly, China ranks higher than India on our Asia Pacific Pharmaceuticals & Healthcare Business Environment Ratings (BERs) for Q310 (4th vs

To read the full article, please choose one of the following options:

Subcribers please log in